User profiles for Weiwei Tan

Weiwei Tan

The Hong Kong Polytechnic University
Verified email at connect.polyu.hk
Cited by 958

Deep learning in environmental remote sensing: Achievements and challenges

…, H Shen, T Li, Z Li, S Li, Y Jiang, H Xu, W Tan… - Remote Sensing of …, 2020 - Elsevier
Various forms of machine learning (ML) methods have historically played a valuable role in
environmental remote sensing research. With an increasing amount of “big data” from earth …

Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement.

…, JW Clark, R Salgia, G Shapiro, YJ Bang, W Tan… - 2012 - ascopubs.org
7508 Background: Chromosomal rearrangements of the ROS1 receptor tyrosine kinase
gene define a new molecular subset of NSCLC. In cell lines, ROS1 rearrangements lead to …

[HTML][HTML] Anaplastic lymphoma kinase inhibition in non–small-cell lung cancer

…, JA Engelman, LV Sequist, WW Tan… - … England Journal of …, 2010 - Mass Medical Soc
Background Oncogenic fusion genes consisting of EML4 and anaplastic lymphoma kinase (ALK)
are present in a subgroup of non–small-cell lung cancers, representing 2 to 7% of such …

[HTML][HTML] Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer

…, RC Doebele, LP Le, Z Zheng, W Tan… - … England Journal of …, 2014 - Mass Medical Soc
Background Chromosomal rearrangements of the gene encoding ROS1 proto-oncogene
receptor tyrosine kinase (ROS1) define a distinct molecular subgroup of non–small-cell lung …

CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib

…, SS Pandya, WL Yeo, Z Shen, W Tan… - Journal of Clinical …, 2011 - ascopubs.org
Discussion Crizotinib (molecular weight, 450.34) is an anaplastic lymphoma kinase (ALK)
tyrosine kinase inhibitor (TKI) 3 that leads to responses in most patients with NSCLC …

[HTML][HTML] Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung …

…, YJ Bang, DW Kim, J Christensen, W Tan… - Journal of thoracic …, 2011 - Elsevier
Crizotinib is a dual MET and ALK inhibitor. Currently, clinical development of crizotinib is
focused primarily on ALK rearranged non-small cell lung cancer (NSCLC). Here we report an …

Viability of the" technology acceptance model" in multimedia learning environments: a comparative study

R Saade, F Nebebe, W Tan - … Journal of E-Learning and Learning …, 2007 - learntechlib.org
In recent years, more and more higher education institutions have interests of integrating
internet-based technologies in the classroom as part of the learning environment. Compared to …

Extending TAM for online learning systems: An intrinsic motivation perspective

S Zhang, J Zhao, W Tan - Tsinghua science and technology, 2008 - ieeexplore.ieee.org
To get a better understanding of user behavior towards online learning systems, the technology
acceptance model (TAM) was extended to include an intrinsic motivational factor. An …

Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers

…, SE DePrimo, S Bentivegna, KD Wilner, W Tan… - Clinical Cancer …, 2010 - AACR
Purpose: To determine tolerability, pharmacokinetics, and pharmacodynamics of PD-0325901,
a highly potent, selective, oral mitogen-activated protein kinase/extracellular signal-…

Dual-drug loaded polysaccharide-based self-healing hydrogels with multifunctionality for promoting diabetic wound healing

W Tan, T Long, Y Wan, B Li, Z Xu, L Zhao, C Mu… - Carbohydrate …, 2023 - Elsevier
Diabetic chronic wound healing still faces huge clinical challenge. The arrangement and
coordination of healing processes are disordered in diabetic wound caused by the persistent …